Immunopathology: Autoimmune glial diseases and differentiation from multiple sclerosis

Bogdan F G H Popescu, Claudia F Lucchinetti

Research output: Chapter in Book/Report/Conference proceedingConference contribution

5 Citations (Scopus)

Abstract

While multiple sclerosis (MS) is often referred to as an autoimmune inflammatory demyelinating disease, neuromyelitis optica (NMO) is currently the only proven and well-characterized autoimmune disease affecting the glial cells. The target antigen is the water channel aquaporin-4 (AQP4), expressed on astrocytes, and antibodies against AQP4 (AQP4-IgG) are present in the serum of NMO patients. Clinical, serologic, cerebrospinal fluid, and neuroimaging criteria help differentiate NMO from other central nervous system inflammatory demyelinating disorders. Pathologically, the presence of dystrophic astrocytes, myelin vacuolation, granulocytic inflammatory infiltrates, vascular hyalinization, macrophages containing glial fibrillary acidic protein-positive debris and/or the absence of Creutzfeldt-Peters cells is more characteristic, but not specific, for NMO. These findings should prompt the neuropathologist to perform AQP4 immunohistochemistry, and recommend serologic testing for AQP4-IgG to exclude a diagnosis of NMO/NMO spectrum disorder (NMOSD). Loss of AQP4 on biopsied active demyelinating lesions and/or seropositivity for AQP4-IgG may confirm the diagnosis of NMO/NMOSD, which is important because treatments that are suitable for MS can aggravate NMO. Few other putative glial antigens have been postulated, but their pathogenic role remains to be demonstrated.

Original languageEnglish (US)
Title of host publicationAutoimmune Neurology, 2016
PublisherElsevier
Pages95-106
Number of pages12
Volume133
ISBN (Print)9780444634320
DOIs
StatePublished - 2016

Publication series

NameHandbook of Clinical Neurology
Volume133
ISSN (Print)00729752
ISSN (Electronic)22124152

Fingerprint

Neuromyelitis Optica
Aquaporin 4
Neuroglia
Autoimmune Diseases
Multiple Sclerosis
Immunoglobulin G
Demyelinating Diseases
Astrocytes
Antigens
Aquaporins
Glial Fibrillary Acidic Protein
Myelin Sheath
Neuroimaging
Blood Vessels
Cerebrospinal Fluid
Central Nervous System
Immunohistochemistry
Macrophages

Keywords

  • Antibody
  • Aquaporin-4
  • Astrocyte
  • Demyelination
  • Microglia
  • Neuromyelitis optica
  • Oligodendrocyte

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Cite this

Popescu, B. F. G. H., & Lucchinetti, C. F. (2016). Immunopathology: Autoimmune glial diseases and differentiation from multiple sclerosis. In Autoimmune Neurology, 2016 (Vol. 133, pp. 95-106). (Handbook of Clinical Neurology; Vol. 133). Elsevier. https://doi.org/10.1016/B978-0-444-63432-0.00006-2

Immunopathology : Autoimmune glial diseases and differentiation from multiple sclerosis. / Popescu, Bogdan F G H; Lucchinetti, Claudia F.

Autoimmune Neurology, 2016. Vol. 133 Elsevier, 2016. p. 95-106 (Handbook of Clinical Neurology; Vol. 133).

Research output: Chapter in Book/Report/Conference proceedingConference contribution

Popescu, BFGH & Lucchinetti, CF 2016, Immunopathology: Autoimmune glial diseases and differentiation from multiple sclerosis. in Autoimmune Neurology, 2016. vol. 133, Handbook of Clinical Neurology, vol. 133, Elsevier, pp. 95-106. https://doi.org/10.1016/B978-0-444-63432-0.00006-2
Popescu BFGH, Lucchinetti CF. Immunopathology: Autoimmune glial diseases and differentiation from multiple sclerosis. In Autoimmune Neurology, 2016. Vol. 133. Elsevier. 2016. p. 95-106. (Handbook of Clinical Neurology). https://doi.org/10.1016/B978-0-444-63432-0.00006-2
Popescu, Bogdan F G H ; Lucchinetti, Claudia F. / Immunopathology : Autoimmune glial diseases and differentiation from multiple sclerosis. Autoimmune Neurology, 2016. Vol. 133 Elsevier, 2016. pp. 95-106 (Handbook of Clinical Neurology).
@inproceedings{f6a44e390a804be687d93967e2ea0833,
title = "Immunopathology: Autoimmune glial diseases and differentiation from multiple sclerosis",
abstract = "While multiple sclerosis (MS) is often referred to as an autoimmune inflammatory demyelinating disease, neuromyelitis optica (NMO) is currently the only proven and well-characterized autoimmune disease affecting the glial cells. The target antigen is the water channel aquaporin-4 (AQP4), expressed on astrocytes, and antibodies against AQP4 (AQP4-IgG) are present in the serum of NMO patients. Clinical, serologic, cerebrospinal fluid, and neuroimaging criteria help differentiate NMO from other central nervous system inflammatory demyelinating disorders. Pathologically, the presence of dystrophic astrocytes, myelin vacuolation, granulocytic inflammatory infiltrates, vascular hyalinization, macrophages containing glial fibrillary acidic protein-positive debris and/or the absence of Creutzfeldt-Peters cells is more characteristic, but not specific, for NMO. These findings should prompt the neuropathologist to perform AQP4 immunohistochemistry, and recommend serologic testing for AQP4-IgG to exclude a diagnosis of NMO/NMO spectrum disorder (NMOSD). Loss of AQP4 on biopsied active demyelinating lesions and/or seropositivity for AQP4-IgG may confirm the diagnosis of NMO/NMOSD, which is important because treatments that are suitable for MS can aggravate NMO. Few other putative glial antigens have been postulated, but their pathogenic role remains to be demonstrated.",
keywords = "Antibody, Aquaporin-4, Astrocyte, Demyelination, Microglia, Neuromyelitis optica, Oligodendrocyte",
author = "Popescu, {Bogdan F G H} and Lucchinetti, {Claudia F}",
year = "2016",
doi = "10.1016/B978-0-444-63432-0.00006-2",
language = "English (US)",
isbn = "9780444634320",
volume = "133",
series = "Handbook of Clinical Neurology",
publisher = "Elsevier",
pages = "95--106",
booktitle = "Autoimmune Neurology, 2016",

}

TY - GEN

T1 - Immunopathology

T2 - Autoimmune glial diseases and differentiation from multiple sclerosis

AU - Popescu, Bogdan F G H

AU - Lucchinetti, Claudia F

PY - 2016

Y1 - 2016

N2 - While multiple sclerosis (MS) is often referred to as an autoimmune inflammatory demyelinating disease, neuromyelitis optica (NMO) is currently the only proven and well-characterized autoimmune disease affecting the glial cells. The target antigen is the water channel aquaporin-4 (AQP4), expressed on astrocytes, and antibodies against AQP4 (AQP4-IgG) are present in the serum of NMO patients. Clinical, serologic, cerebrospinal fluid, and neuroimaging criteria help differentiate NMO from other central nervous system inflammatory demyelinating disorders. Pathologically, the presence of dystrophic astrocytes, myelin vacuolation, granulocytic inflammatory infiltrates, vascular hyalinization, macrophages containing glial fibrillary acidic protein-positive debris and/or the absence of Creutzfeldt-Peters cells is more characteristic, but not specific, for NMO. These findings should prompt the neuropathologist to perform AQP4 immunohistochemistry, and recommend serologic testing for AQP4-IgG to exclude a diagnosis of NMO/NMO spectrum disorder (NMOSD). Loss of AQP4 on biopsied active demyelinating lesions and/or seropositivity for AQP4-IgG may confirm the diagnosis of NMO/NMOSD, which is important because treatments that are suitable for MS can aggravate NMO. Few other putative glial antigens have been postulated, but their pathogenic role remains to be demonstrated.

AB - While multiple sclerosis (MS) is often referred to as an autoimmune inflammatory demyelinating disease, neuromyelitis optica (NMO) is currently the only proven and well-characterized autoimmune disease affecting the glial cells. The target antigen is the water channel aquaporin-4 (AQP4), expressed on astrocytes, and antibodies against AQP4 (AQP4-IgG) are present in the serum of NMO patients. Clinical, serologic, cerebrospinal fluid, and neuroimaging criteria help differentiate NMO from other central nervous system inflammatory demyelinating disorders. Pathologically, the presence of dystrophic astrocytes, myelin vacuolation, granulocytic inflammatory infiltrates, vascular hyalinization, macrophages containing glial fibrillary acidic protein-positive debris and/or the absence of Creutzfeldt-Peters cells is more characteristic, but not specific, for NMO. These findings should prompt the neuropathologist to perform AQP4 immunohistochemistry, and recommend serologic testing for AQP4-IgG to exclude a diagnosis of NMO/NMO spectrum disorder (NMOSD). Loss of AQP4 on biopsied active demyelinating lesions and/or seropositivity for AQP4-IgG may confirm the diagnosis of NMO/NMOSD, which is important because treatments that are suitable for MS can aggravate NMO. Few other putative glial antigens have been postulated, but their pathogenic role remains to be demonstrated.

KW - Antibody

KW - Aquaporin-4

KW - Astrocyte

KW - Demyelination

KW - Microglia

KW - Neuromyelitis optica

KW - Oligodendrocyte

UR - http://www.scopus.com/inward/record.url?scp=84978387415&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978387415&partnerID=8YFLogxK

U2 - 10.1016/B978-0-444-63432-0.00006-2

DO - 10.1016/B978-0-444-63432-0.00006-2

M3 - Conference contribution

C2 - 27112673

AN - SCOPUS:84978387415

SN - 9780444634320

VL - 133

T3 - Handbook of Clinical Neurology

SP - 95

EP - 106

BT - Autoimmune Neurology, 2016

PB - Elsevier

ER -